IP Library Granted Patent US 8,277,799
Granted Patent B2
US 8,277,799 · App. 12/756,658 · Granted Oct 2, 2012

Inhibition of pathogens by probiotic bacteria

Assignee: Ganeden Biotech, Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,277,799
App. No.
12/756,658
Granted
Oct 2, 2012
Kind
B2
Abstract

Compositions containing a lactic acid-producing bacterial strain, e.g., Bacillus coagulans for inhibition of pathogenic bacterial infections. Spores or extracellular products produced by the bacterial strains are also useful as inhibitory agents.

Claims (11)

1. A method of maintaining gastrointestinal tract health comprising administering to the gastrointestinal tract of a mammal a composition comprising an isolated Bacillus coagulans GBI-30 strain (ATCC Designation Number PTA-6086), wherein said strain colonizes the gastrointestinal tract of said mammal to maintain gastrointestinal health.

2. The method of claim 1 , wherein said composition is administered orally, buccally, or nasally.

3. The method of claim 1 , wherein said composition is administered in a food or as a food supplement.

4. The method of claim 1 , wherein said strain produces lactic acid and has an optimal growth temperature of in the range of 25-35° C.

5. The method of claim 1 , wherein said strain produces lactic acid and has an optimal growth temperature of 30° C.

6. The method of claim 1 , wherein said strain produces L(+) dextrorotatory lactic acid and produces spores resistant to temperatures of up to approximately 90° C.

7. The method of claim 1 , wherein said composition comprises a viable Bacillus coagulans GBI-30 strain (ATCC Designation Number PTA-6086) vegetative bacterial cell.

8. The method of claim 1 , wherein said composition comprises a viable Bacillus coagulans GBI-30 strain (ATCC Designation Number PTA-6086) bacterial spore.

9. The method of claim 1 , wherein said composition comprises 1×10 3 to 1×10 14 CFU of Bacillus coagulans GBI-30 strain (ATCC Designation Number PTA-6086).

10. The method of claim 1 , wherein said composition comprises 1×10 8 to 1×10 10 CFU of Bacillus coagulans GBI-30 strain (ATCC Designation Number PTA-6086).

11. The method of claim 1 , wherein said composition comprises 1×10 9 CFU of Bacillus coagulans GBI-30 strain (ATCC Designation Number PTA-6086).

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Sep 12, 2017
From: SILICON VALLEY BANK
To: GANEDEN BIOTECH, INC.
Reel/Frame 043822/0897 →
SECURITY AGREEMENT Recorded Oct 10, 2012
From: GANEDEN BIOTECH, INC.
To: SILICON VALLEY BANK
Reel/Frame 029103/0069 →
LICENSE Recorded Jul 19, 2011
From: GANEDEN BIOTECH, INC.
To: SCHIFF NUTRITION GROUP, INC.
Reel/Frame 026616/0128 →
SECURITY AGREEMENT Recorded Jul 19, 2011
From: GANEDEN BIOTECH, INC.
To: SCHIFF NUTRITION GROUP, INC.
Reel/Frame 026616/0950 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2010
From: FARMER, SEAN
To: GANEDEN BIOTECH, INCORPORATED
Reel/Frame 025144/0519 →
Continuity (6)
Division 11706642 · Feb 13, 2007
Continuation 11005897 · Dec 16, 2004
Continuation 09708870 · Nov 8, 2000
Provisional Application 60163959 · Nov 8, 1999
Provisional Application 60198404 · Apr 19, 2000
Related Publication 20110189145A1 · Aug 4, 2011